Download Files:
Olmesartan-d6
SKU
HY-17004S1-1 mg
Category Isotope-Labeled Compounds
Tags Angiotensin Receptor;Isotope-Labeled Compounds, Cardiovascular Disease, GPCR/G Protein;Others
$425
Only 1000 item(s) left in stock.
Products Details
Product Description
– Olmesartan-d6 (RNH-6270-d6) is the deuterium labeled Olmesartan. Olmesartan (RNH-6270) is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure[1][2].
Web ID
– HY-17004S1
Shipping
– Room temperature
Molecular Formula
– C24H20D6N6O3
References
– [1]Bakhtiari E, et al. Synergistic, cytotoxic and apoptotic activities of olmesartan with NF-κB inhibitor against HeLa human cell line. Toxicol Mech Methods. 2015;25(8):614-21.|[2]Tanno T, et al. Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression. J Cardiovasc Pharmacol. 2016 Jun;67(6):503-9.|[3]Yanagihara H, et al. Effects of telmisartan and olmesartan on insulin sensitivity and renal function in spontaneously hypertensive rats fed a high fat diet. J Pharmacol Sci. 2016 Jul;131(3):190-7.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
CAS Number
– 1185144-74-4
Molecular Weight
– 452.54
SMILES
– OC(C(N1CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2)=C(N=C1CCC)C(C([2H])([2H])[2H])(O)C([2H])([2H])[2H])=O
Clinical Information
– No Development Reported
Research Area
– Cardiovascular Disease
Solubility
– 10 mM in DMSO
Target
– Angiotensin Receptor;Isotope-Labeled Compounds
Isoform
– AT1 Receptor
Pathway
– GPCR/G Protein;Others
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.